|
tbar.gif
Click
here to
submit entries
|
|
|
Presidio
Paying Up To $108M for XTL’s HCV Program
|
March
20, 2008--Presidio
Pharmaceuticals has obtained an exclusive, worldwide license to XTL
Biopharmaceuticals’ proprietary HCV NS5A program. Presidio will assume
responsibility for any additional lead optimization, clinical development,
and commercialization activities related to the program. XTL will receive
$4 million upfront and could earn an additional $104 million if all
development and commercialization milestones are achieved. Presidio
Pharmaceuticals
|
|
|
Genstruct: Patience, Persistence, and Payoff
By John Russell |
|
Finding the right business model for systems biology (SB) technology providers has been challenging — that’s hardly a new theme in biotech.
Click
here
|
|
|
